Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 19, 2015, Pages 6140-6145

  Romano, Emanuela ^a   Kusio Kobialka, Monika ^a   Foukas, Periklis G ^a,b   Baumgaertner, Petra ^a   Meyer, Christiane ^a   Ballabeni, Pierluigi ^c   Michielin, Olivier ^a   Weide, Benjamin ^d   Romero, Pedro ^a   Speiser, Daniel E ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

ADCC; Ipilimumab; Macrophage; Monocytes; Tregs

Indexed keywords

CD16 ANTIGEN; IPILIMUMAB; ANTINEOPLASTIC AGENT; CD14 ANTIGEN; CD3 ANTIGEN; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; FC RECEPTOR; FCGR3B PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS MELANOMA; CYTOTOXICITY ASSAY; DRUG CYTOTOXICITY; DRUG MEGADOSE; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; MELANOMA METASTASIS; MONOCYTE; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR BIOPSY; TUMOR MICROENVIRONMENT; VERY ELDERLY; ANIMAL; BLOOD; CELL SEPARATION; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; IMMUNOLOGY; MACROPHAGE; MELANOMA; METABOLISM; MIDDLE AGED; MOUSE; SKIN NEOPLASMS;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GPI-LINKED PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MELANOMA; MICE; MIDDLE AGED; RECEPTORS, IGG; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 84929192743     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1417320112     Document Type: Article

References (30)

1. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252-264.
2. Hodi FS, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711-723.
3. Robert C, et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517-2526.
4. Pardoll DM (2012) Immunology beats cancer: A blueprint for successful translation. Nat Immunol 13(12):1129-1132.
5. Bachmann MF, Köhler G, Ecabert B, Mak TW, Kopf M (1999) Cutting edge: Lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol 163(3):1128-1131.
6. Walker LS, Sansom DM (2011) The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 11(12):852-863.
7. Wang CJ, et al. (2012) Cutting edge: Cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells. J Immunol 189(3):1118-1122.
8. Bulliard Y, et al. (2013) Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 210(9):1685-1693.
9. Selby MJ, et al. (2013) Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1(1):32-42.
10. Simpson TR, et al. (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210(9):1695-1710.
11. Wolchok JD, et al. (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15(23):7412-7420.
12. Cros J, et al. (2010) Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 33(3):375-386.
13. Ziegler-Heitbrock L (2007) The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol 81(3):584-592.
14. Gordon S, Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5(12):953-964.
15. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8(1):34-47.
16. Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310(5753):1510-1512.
17. Ziegler-Heitbrock L, Hofer TP (2013) Toward a refined definition of monocyte subsets. Front Immunol 4:23.
18. Biburger M, et al. (2011) Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 35(6):932-944.
19. Wing K, et al. (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322(5899):271-275.
20. Chung DJ, et al. (2009) Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 114(3):555-563.
21. Seddiki N, et al. (2006) Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203(7):1693-1700.
22. Liu W, et al. (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203(7):1701-1711.
23. Viguier M, et al. (2004) Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173(2):1444-1453.
24. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A (2013) A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol 6:1.
25. Sica A, Mantovani A (2012) Macrophage plasticity and polarization: In vivo veritas. J Clin Invest 122(3):787-795.
26. Heusinkveld M, van der Burg SH (2011) Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 9:216.
27. Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat Immunol 11(10):889-896.
28. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11):549-555.
29. Quezada SA, Peggs KS, Curran MA, Allison JP (2006) CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116(7):1935-1945.
30. Hodi FS, et al. (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105(8):3005-3010.